PTPRC and chronic myelogenous leukemia, BCR-ABL1 positive: To understand the immune landscape of CP-CML during dasatinib plus IFN-α treatment, we analyzed over 100,000 flow cytometry–sorted CD45+ blood mononuclear cells from 12 samples with scRNA-seq and scTCRαβ-seq (10× Genomics, n = 4; samples at 0, 3, and 12 months; 2 patients with PE and 2 patients without adverse effects; patient details in Supplemental Table 1).